Candel Therapeutics, Inc. (CADL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$12.78-1.46%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CADL
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | — | — | — | 0.1 | 0.1 | 0.1 |
| Operating Expenses & Income | |||||||
| R&D Expenses | 49.1 | 30.5 | 19.3 | 24.5 | 20.8 | 15.2 | 8.8 |
| Operating Income | (72.0) | (48.3) | (33.4) | (38.4) | (34.7) | (25.7) | (13.8) |
| Earnings from Continuing Operations | |||||||
| Interest Expense | 4.7 | 2.1 | 2.1 | (2.6) | 1.7 | — | — |
| Interest & Investment Income | — | — | — | 2.1 | 1.2 | — | — |
| Net Interest Expenses | — | — | — | (4.7) | 0.5 | — | — |
| Other Non-Operating Income / Expenses | (16.5) | 10.1 | (21.8) | 0.5 | 15.9 | (10.4) | (3.9) |
| EBT, Incl. Unusual Items | — | (38.2) | — | — | — | — | — |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | — |
| Net Income | |||||||
| Net Income | (88.5) | (38.2) | (55.2) | (37.9) | (18.8) | (36.1) | (17.7) |
| Per Share | |||||||
| Basic EPS | (1.19) | (0.72) | (1.74) | (1.31) | (0.65) | (1.91) | — |
| Diluted EPS | (1.19) | (0.72) | (1.74) | (1.31) | (0.65) | (1.91) | — |
| Basic Weighted Avg Shares | 74.1 | 53.0 | 31.7 | 28.9 | 28.8 | 18.9 | — |
| Diluted Weighted Avg Shares | 74.1 | 53.0 | 31.7 | 28.9 | 28.8 | 18.9 | — |
| Supplemental | |||||||
| EBITDA | — | — | — | — | (33.9) | (25.5) | (13.7) |
| EBIT | (72.0) | (48.3) | (33.4) | (38.4) | (34.7) | (25.7) | (13.8) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.